Evofem Biosciences (EVFM) Price & Analysis

Q: What was Evofem Biosciences’s price range in the past 12 months?

Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.

Q: What is Evofem Biosciences’s market cap?

Evofem Biosciences’s market cap is $1.14M.

Q: When is Evofem Biosciences’s upcoming earnings report date?

Evofem Biosciences’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.

Q: Is Evofem Biosciences overvalued?

According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Evofem Biosciences pay dividends?

Evofem Biosciences does not currently pay dividends.

Q: What is Evofem Biosciences’s EPS estimate?

Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Evofem Biosciences have?

Evofem Biosciences has 126,685,930 shares outstanding.

Q: Which hedge fund is a major shareholder of Evofem Biosciences?

Currently, no hedge funds are holding shares in EVFM

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

1,207 Followers

EVFM Stock Chart & Stats

$0.01

>-$0.01(-8.76%)

At close: Jan 08 4:00 PM EST

$0.01

>-$0.01(-8.76%)

Day’s Range― - ―

52-Week Range<$0.01 - $0.02

Previous CloseN/A

Volume1.62M

Average Volume (3M)589.38K

Market Cap

$1.14M

Enterprise Value$65.98M

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$64.82M

Price to Earnings (P/E)―

Beta0.01

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding126,685,930

10 Day Avg. Volume412,838

30 Day Avg. Volume589,380

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.01

Price to Sales (P/S)0.05

P/FCF Ratio-0.24

Enterprise Value/Market Cap57.87

Enterprise Value/Revenue3.72

Enterprise Value/Gross Profit4.68

Enterprise Value/Ebitda-31.94

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)57.5

Revenue Forecast (FY)$241.13M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe significant revenue growth indicates strong market demand for Evofem's products, particularly Phexxi, suggesting potential for future expansion.

Product InnovationEvofem's focus on non-hormonal contraceptive solutions positions it well in a growing niche market, potentially driving long-term competitive advantage.

Market PositionBy targeting a specific demographic with unmet needs, Evofem can strengthen its market position and build brand loyalty over time.

Bears Say

High LeverageHigh leverage and negative equity pose significant financial risks, potentially limiting the company's ability to invest in growth and innovation.

Cash Flow ChallengesPersistent negative cash flow indicates reliance on external financing, which could hinder operational flexibility and long-term sustainability.

Profitability IssuesOngoing profitability challenges highlight operational inefficiencies, which may affect the company's ability to achieve sustainable growth.

Evofem Biosciences News

Evofem Biosciences posts updated corporate investor presentation

The latest announcement is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences, Inc. reported that it periodically...

2M ago

EVFM

Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals

The latest update is out from Evofem Biosciences ( ($EVFM) ). Evofem Biosciences held its Annual Meeting on...

3M ago

EVFM

Evofem Biosciences Reports Q3 2025 Earnings

Evofem Biosciences, Inc. ( ($EVFM) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

EVFM

Evofem Biosciences Ends Merger with Aditxt, Refocuses Strategy

Evofem Biosciences ( ($EVFM) ) has provided an announcement. On October 20, 2025, Evofem Biosciences announced the termination...

4M ago

EVFM

Evofem Biosciences Amends Securities Purchase Agreement

An announcement from Evofem Biosciences ( ($EVFM) ) is now available. On October 13, 2025, Evofem Biosciences amended...

5M ago

EVFM

Evofem Biosciences Updates Merger Agreement with Aditxt

Evofem Biosciences ( ($EVFM) ) has issued an announcement. Evofem Biosciences, in collaboration with Aditxt, Inc., has entered...

6M ago

EVFM

Evofem says FDA Orange Book lists patent for Solosec treatment

Evofem (EVFM) Biosciences announced that a newly-issued U.S. patent which covers SOLOSEC 2 g oral granules and one...

7M ago

EVFM

Evofem Biosciences Reports Positive Q2 2025 Results

Evofem Biosciences, Inc. ( ($EVFM) ) has released its Q2 earnings. Here is a breakdown of the information...

7M ago

EVFM

Evofem Biosciences Enters Securities Purchase Agreement

Evofem Biosciences ( ($EVFM) ) has provided an announcement. On June 26, 2025, Evofem Biosciences, Inc. entered into...

8M ago

EVFM

Evofem announces Emirati health care filed application with UAE MOHAP

Evofem (EVFM) Biosciences announced that private Emirati health care company Pharma 1 Drug Store LLC has filed an...

8M ago

EVFM

Aditxt appoints Evofem CEO Saundra Pelletier to board

Aditxt (ADTX) announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences (EVFM) to Aditxt’s board of directors....

9M ago

ADTX

EVFM

Evofem Biosciences Signs Agreement with Pharma 1

Evofem Biosciences ( ($EVFM) ) has provided an announcement. On May 19, 2025, Evofem Biosciences entered into a...

10M ago

EVFM

Evofem Biosciences Reports Q1 2025 Earnings

Evofem Biosciences, Inc. ( ($EVFM) ) has released its Q1 earnings. Here is a breakdown of the information...

10M ago

EVFM

Evofem announces license and supply agreement with Windtree Therapeutics

Evofem Biosciences (EVFM) announced that it has entered into a License and Supply Agreement with Windtree Therapeutics (WINT),...

11M ago

EVFM

WINT

EVFM FAQ

What was Evofem Biosciences’s price range in the past 12 months?

Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.

What is Evofem Biosciences’s market cap?

Evofem Biosciences’s market cap is $1.14M.

When is Evofem Biosciences’s upcoming earnings report date?

Evofem Biosciences’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.

How were Evofem Biosciences’s earnings last quarter?

Currently, no data Available

Is Evofem Biosciences overvalued?

According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Evofem Biosciences pay dividends?

Evofem Biosciences does not currently pay dividends.

What is Evofem Biosciences’s EPS estimate?

Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Evofem Biosciences have?

Evofem Biosciences has 126,685,930 shares outstanding.

What happened to Evofem Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Evofem Biosciences?

Currently, no hedge funds are holding shares in EVFM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.